SecBot SecBot
SECBOTREPLAY Home › Report › GSK

GSK · GSK announced plans to build a new flagship R&D centre on the Cambridge…

GSK plc · 6-K filed Jul 28, 2026 at 13:10 ET

At the news

NEUTRALIMPACT 4/10

6-K filed Jul 28, 2026 at 13:10 ET

GSK announced plans to build a new flagship R&D centre on the Cambridge Biomedical Campus in the UK, with a £400 million investment over three years. The 300,000 sq ft site will consolidate UK R&D operations, housing over 1,000 scientists focused on Oncology, Respiratory, Hepatology, Vaccines, and HIV, while vacating the Stevenage site by 2029. This is a long-term infrastructure commitment with no immediate financial impact on earnings or guidance, and the stock impact is likely neutral in the near term.

  • GSK plans a £400 million investment over 3 years to establish a new R&D centre on the Cambridge Biomedical Campus in the UK.
  • The new 300,000 square foot site will house over 1,000 GSK scientists and consolidate UK R&D operations.
  • GSK will vacate its existing R&D site at Stevenage, with a phased employee move by 2029.
  • The company will also upgrade its R&D laboratories at Ware, Hertfordshire, as part of the plan.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access